#United States #Washington D.C. #Mallinckrodt #Hepatorenal Syndrome #Terlipressin

Mallinckrodt's Upcoming Presentation at AASLD 2025

Mallinckrodt plc, a renowned specialty pharmaceutical company, is set to present compelling research data on Terlipressin at the esteemed 2025 American Association for the Study of Liver Diseases (AASLD) Annual Meeting. The event will take place in Washington, D.C., from November 7 to 11, 2025. Mallinckrodt will feature four significant posters, notably including a Poster of Distinction, which showcases vital findings in the treatment of hepatorenal syndrome (HRS).

The Significance of Terlipressin

Terlipressin, branded as TERLIVAZ®, holds the distinction of being the first FDA-approved pharmacological treatment aimed at enhancing kidney function in adults suffering from HRS, specifically those facing rapid declines in kidney health or acute kidney injury (AKI). This life-threatening condition affects more than 60,000 individuals in the U.S. annually, emphasizing the relevance of this treatment. Though HRS is a rare condition, its rising hospitalization rates accentuate the urgent need for effective therapeutic interventions.

Insights from the Research

During the AASLD meeting, Dr. Christopher White, Senior Director and Hepatology Lead at Mallinckrodt, commented on the importance of these presentations. He expressed gratitude towards the study participants and teams who made these analyses possible. This collaborative effort has empowered both physicians and patients with newfound knowledge about HRS, fostering a deeper understanding of this complex health challenge.

The posters will cover various analyses, including:

• - AASLD Poster of Distinction: Focus on promising findings in treating HRS.
• - Patient Impact: Discussions on how Terlipressin is transforming management strategies for renal function in HRS cases.

Presentation Details

The specific session titled “Portal Hypertension and Other Complications of Cirrhosis” is scheduled for November 8, 2025, from 8:00 a.m. to 5:00 p.m. ET. Below are the titles and presenters for the posters to be showcased:

• - Poster #2285 (AASLD Poster of Distinction): Presented by Kavish R. Patidar, DO
• - Poster #2401: Presented by A. Sidney Barritt IV, MD
• - Poster #2315: Presented by R. Todd Frederick, MD
• - Poster #2380: Presented by Xingyue Huang, PhD

This comprehensive exploration into HRS via Terlipressin illustrates Mallinckrodt's commitment to addressing unmet medical needs in this critical area.

Understanding Hepatorenal Syndrome (HRS)

HRS poses a severe threat, usually occurring with advanced liver disease, and is classified into two types: one being rapidly progressive (HRS-AKI) leading to renal failure with a short median survival time if untreated. The detrimental impact is evident, with rates of mortality reaching over 80% within three months in untreated cases. This pressing reality highlights the indispensable role of effective treatments like Terlipressin.

Looking Ahead

As Mallinckrodt continues its dedication to transforming treatment outcomes, the research presented at AASLD is a testament to the advancements they’re making in addressing serious conditions. Their ongoing commitment ensures that innovations in pharmaceuticals are available to those in desperate need.

For updates and further information about Mallinckrodt and their advancements, visit their official website at www.MNK-Endo.com.